Clinical Case Scenario. HIVeEducation Workshop, Sint Maarten 2009

Similar documents
nevirapine, stavudine and lamivudine

nevirapine, zidovudine and lamivudine

Efavirenz, stavudine and lamivudine

Principles of Antiretroviral Therapy

National Clinical Symposium

ANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL

d4t-3tc-nvp stavudine lamivudine nevirapine Morning: d4t-3tc-nvp (Combined tablet) Evening: d4t and 3TC (2 separate tablets)

Difference of opinion? Michelle Moorhouse 24 Sep 2014

MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015

Immune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela

INITIATING ART IN CHILDREN: Follow the six steps

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

medical monitoring: clinical monitoring and laboratory tests

Description of d4t toxicities among 3 OI/ART clinics patients on ARV in Cambodia

BASIC HIV COURSE EXAMINATION

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

ADVANCED CLINICAL CARE JOB AIDES VERSION1- MARCH 2018

Post-Exposure Prophylaxis Review for International Visitors

ABACAVIR HYPERSENSITIVITY REACTION

SA TB Guidelines The interface with Advanced Clinical Care

TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011

Clinical Management Guidelines 2012

What Women Need to Know: The HIV Treatment Guidelines for Pregnant Women

treatment during pregnancy and breastfeeding

Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for

Antiretroviral Drugs. Paediatric Palliative Care For Home Based Carers. Funded by British High Commission, Pretoria Small Grant Scheme

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus

Treatment and Monitoring

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

Treatment strategies for the developing world

Continuing Education for Pharmacy Technicians

Clinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years. SAHIVCS - CME 13/06/15 DR.Henry Sunpath

UPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

A Genetic Test to Screen for Abacavir Hypersensitivity Reactions

Clinical Manifestations of HIV

CLAUDINE HENNESSEY & THEUNIS HURTER

3TC (lamivudine, Epivir)

3TC (lamivudine, Epivir)

World Bank Training Program on HIV/AIDS Drugs

Int. J. Adv. Res. Biol. Sci. (2017). 4(8): 28-35

Sasisopin Kiertiburanakul, MD, MHS

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Newly diagnosed HIV patient. Dr. Heila Redpath 06 FEBRUARY 2014

Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment

TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers

Diagnosis and Treatment of Tuberculosis, 2011

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

HIV and AIDS. Shan Nanji

MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen)

TOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY

Module 6: ARVs in Children

Medical monitoring: Clinical monitoring and laboratory tests

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

HIGHLIGHTS OF PRESCRIBING INFORMATION

Paediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016

REVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)

Introduction: WHO recommends that criteria for starting ART be defined in national protocols and that these

Treatment of Latent TB Infection (LTBI)

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

LTBI Videos-Treatment

Clinical Characteristics and The Selection of Initial ARV Regimen Therapy for HIV-Infected Patients in VCT-CST RSUP Sanglah, Denpasar

SA HIV Clinicians Society Adult ART guidelines

VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008

Monitoring During Antiretroviral Therapy: Issues and Concerns. Subhasish Kamal Guha

HIV Treatment. Why do I need to know about HIV treatment?

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa

Lactic Acidosis and Ascending Neuromuscular Syndrome. Mina Hosseinipour, M.D, MPH. University of North Carolina Project, Lilongwe Malawi

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Supplementary Methods. HIV Synthesis Transmission V1. Model details

Adult Guidelines. Sipho Dlamini. Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital

Year 2002 Paper two: Questions supplied by Jo 1

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

BHIVA Clinical Audit. Management of patients who switch therapy; re-audit of patients starting therapy from naïve

Section 4: Side effects of ARVs. 4.1 Introduction. 4.2 Aims for this section

EFAVIRENZ ASSOCIATED STEVENS-JOHNSON SYNDROME

Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for

GUIDELINES FOR THE USE OF ANTIRETROVIRAL THERAPY IN PAPUA NEW GUINEA

Treatment of MDR-TB in high HIV- prevalence settings. Hind Satti, M.D. PIH-Lesotho October 20, 2008

THE STAGING AND MEDICATION OF HIV INFECTION

Int. J. Pharm. Sci. Rev. Res., 26(2), May Jun 2014; Article No. 15, Pages: 79-83

Medical PCCN. AACN Progressive Critical Care Nursing.

Figure S1: Overview of PMTCT Options A and B. Prevention of Mother to Child HIV Transmission (PMTCT)

Reasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia.

Elements for a public summary

Tocilizumab (Actemra )

3 East and Central African Journal of Pharmaceutical Sciences Vol. 16 (2013) 3-12

The Hospitalized HIV+ Patient

HIGHLIGHTS OF PRESCRIBING INFORMATION

Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for

Reaching HIV-1 Treatment Decisions Without a Patient s Medical Records

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

Objectives. 3HP and Flu Syndrome What is the Underlying Mechanism? Case #1 3/23/2016. Christina T. Fiske, MD MPH March 30, 2016

Clinical skills building - HIV drug resistance

ABACAVIR HYPERSENSITIVITY REACTION

CASE-BASED SMALL GROUP DISCUSSION

Transcription:

Clinical Case Scenario HIVeEducation Workshop, Sint Maarten 2009

Background Mrs. S is a 34 year-old woman who was referred from the VCT center after testing HIV positive three weeks ago. Her husband recently died from cryptococcal meningitis; during his hospitalization he tested positive for HIV, causing her to pursue testing.

Background, continued Mrs. S s past medical history is remarkable for an appendectomy performed at age 18. She has otherwise been well until her diagnosis for tuberculosis 4 months ago. At that time she began four-drug treatment for TB, and is currently taking isoniazid and ethambutol. HIV testing was recommended and refused at the time of TB diagnosis. Other than TB treatment, she is taking no medications.

Allergies She is allergic to trimethoprim/sulfamethoxazole (Bactrim) which causes a diffuse erythematous maculopapular rash.

Physical exam Her physical exam is notable for a thin, welldeveloped woman in no acute distress. HEENT exam reveals candida on the tongue and buccal mucosa. Heart, lung, and abdomen exam are normal.

Hemoglobin11.7 ALT39 White blood cell4.8 AST47 Neutrophils74% Lymphocytes20% Monocytes6% Platelets167,000 HIV+ Laboratory test

For this patient, what evidence (history, physical examination, and/or laboratory data) supports beginning antiretroviral therapy (ART)? Thrush; oral candida (candidiasis) Low total lymphocyte (lymphs) count (TLC); total TLC = 960; TLC, 1,200 Tuberculosis within past two years; recent tuberculosis HIV+ Social history: husband died of cryptococcal meningitis-likely more advanced disease, so wife likely has been infected for a while.

Do you identify any barriers to good ARV adherence? If so, what would you recommend to address the barrier's? Widowed; limited (or unknown) support system TB (tuberculosis) meds; concurrent TB treatment Finances; limited money Limited knowledge of HIV Not previously ill; good baseline health; no symptoms Potential childrearing responsibilities; potential pregnancy In favor of adherence she opted for testing when her husband was positive In favor of adherence by taking TB drugs she is demonstrating her capacity to take drugs over time The fact that she refused to go for testing The reaction to Septrin may make her hesitant to take more drugs

What antiretroviral medications would you initiate? AZT (Zidovudine) + 3TC + nevirapine (patient already has anemia which might be worsened by AZT) Stavudine (d4t), lamivudine (3TC) and Nevirapine) (lowest cost)

What antiretroviral medications would you initiate? Acceptable alternate regimens: AZT (Zidovudine) + 3TC + efavirenz (patient already has anemia which could be worsened by AZT) d4t (Stavudine) + 3TC + nevirapine more expensive than whats above and need to make sure she isn t pregnant or expecting to become pregnant d4t (Stavudine) + 3TC + efavirenz

What antiretroviral medications would you initiate? Not acceptable Less than three medications Medications which are not antiretrovirals

What toxicities could be associated with the antiretroviral medication s AZT Anemia Nail changes Macrocytosis Fatigue Nausea; GI disturbance Lactic acidosis Hepatic (liver) toxicity myopathy you chose?

What toxicities could be associated with the antiretroviral medication s you chose? 3TC Lactic acidosis Hepatic (liver) toxicity Nausea; GI disturbance Rash (rare)

What toxicities could be associated with the antiretroviral medication s you chose? d4t Nausea; GI disturbance Peripheral neuropathy Lipodystrophy Pancreatitis Lactic acidosis Hepatic (liver) toxicity

What toxicities could be associated with the antiretroviral medication s Efavirenz you chose? Nausea; GI disturbance Central nervous system (CNS) hyperactivity; abnormal dreams; hallucination Rash Hepatic (liver) toxicity Teratogenic (in monkeys)

What toxicities could be associated with the antiretroviral medication s you chose? Nevirapine Rash Nausea; GI disturbance Hepatic (liver) toxicity

Additional Information You and your patient decide to begin antiretroviral therapy. Ten days after starting therapy, she calls to report that she has developed a red, pruritic rash covering most of her trunk and extremities. She denies fever, myalgias, other constitutional symptoms, and says she feels well except for the rash.

Which antiretroviral medication(s) would be the most likely explanation for her symptoms? Best answer Nevirapine Acceptable answer Efavirenz

How would you manage the problem of her rash? Check LFTs (liver function tests) Treat with diphenhydramine (Benadryl) Treat with steroid cream Check hemoglobin and/or hematocrit Continue ART Observe for worsening (worse rash; fever, abdominal pain; mucosal involvement [oral rash, mouth lesions]) Make sure patient started nevirapine with only once daily-if not reduce dose to once daily and when rash resolves increase to twice daily